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I. Introduction
Fabry disease is one of the lysosomal storage 
diseases that was first reported by the German der-
matologist Fabry1) and the British dermatologist 
Anderson2) in 1898. The incidence is about three 
thousandths. It is an X-linked inherited disease 
associated with genetic deficiency of α-galactosi-
dase A (GLA), one of the lysosomal enzymes. Be-
cause of the deficiency of this enzyme, hydrolysis 
of sphingolipids is impaired in the lysosomes, and 
glycolipids such as GL-3 and Gb-3 accumulate in 
various cells of the body, such as the vascular en-
dothelial cells and cardiomyocytes. According to 
a study of the renal histopathological findings in 
childhood-pubertal Fabry disease, the swelling of 
the glomerular epithelial cells, the microvesicular 
degeneration of the endoplasmic reticulum, and a 
zebra pattern within the glomerular epithelial cells 
are already evident before the appearance of overt 
proteinuria. A deposit called a skin-like inclusion 
body, the zebra body, is also recognized3). There-
fore, the detection of mulberry cells and mulber-
ry bodies in the urinary sediment is expected to 
play a role in the diagnosis of Fabry disease at the 
early stage. It has been reported that the detection 
of mulberry cells and mulberry bodies is effective 
for the early detection of Fabry disease because it 
is non-invasive and simple4–6). Currently, the mul-
berry cells and mulberry bodies are not an essen-
tially parthological evidence in urine sediment for 
Fabry disease. Therefore, there is no standardized 
procedures for the detection of mulberry cells and 
mulberry bodies in the urine yet.
We encountered two cases of Fabry disease, 
a mother and her second son, in whom mulber-
ry cells and mulberry bodies were detected in the 
urine. In order to enhance the detection efficiency 
and the clinical significance of mulberry cells and 
mulberry bodies in urine, the urine collection, the 
magnification of microscope, the differentiation 
for the mulberry cells and mulberry bodies from 
other fats and fat-containing cells and fatty parti-
cles, composition and the origin, and the morpho-
logical changes by enzyme replacement therapy 
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(ERT) were examined. 
 
II. Case
At the age of 37 and 9 years old, the second 
son had terminal pain in the extremities at the time 
of fever, and at the age of 12 years, a mother who 
was a carrier was admitted to the Department of 
Pediatrics with suspected Fabry disease. A de-
crease in the GLA activity was confirmed in the 
patients, confirming the diagnosis of Fabry dis-
ease. At the age of 23, the patient became aware 
of dizziness and developed seizures, and at the age 
of 25, although his other renal function parameters 
were maintained, a urinary test showed proteinuria 
(2+). Renal biopsy was performed to confirm the 
degree of renal dysfunction associated with Fabry 
disease. Since the proteinuria persisted, the pa-
tient was started on enzyme replacement therapy 
with agalsidase beta (Fabrazyme®) at the age of 
27 years. 
The mother of the male patient had been di-
agnosed as having hypertension since she was 40 
years old. She had been treated by the department 
of cardiovascular medicine for a long period, 
because she had also been diagnosed as having 
hypertrophy. The urinary sediment showed mul-
berry bodies. Electrocardiography showed the ST 
depression in leads V5 and V6, Echocardiography 
showed left ventricular hypertrophy (left ven-
tricular mass index 186 g/m2), and cardiac MRI 
showed fat deposition in the myocardium. 
Fabry disease was suspected, and a renal bi-
opsy was performed to confirm the diagnosis. 
Twenty-four glomeruli were collected and 5 were 
completely indurated. Podocyte swelling was ob-
served and the cytoplasm was scattered. Based 
on the findings she was diagnosed with of Fabry 
disease and started to be treated with ERT (Fab-
razyme®). 
III. Materials and Methods
1. Urine collection, specimen preparation and 
microscopy
For the observation of the urinary sediment, 
the early morning urine or random urine is accept-
able. However, it is recommended to collect the 
mid-stream of random urine for the convenience 
to patients. Therefore, the mid-steam random 
urine was applied. The urine specimens were cen-
trifuged at 500×g for 5 minutes. The supernatant 
was removed, and the pellet was resuspended in a 
total volume of 200 μL. The suspension was well 
mixed and 15 μL was loaded on to a slide glass 
covered by a piece of 18×18 coverslip for the 
bright field microscopic observation. After wash-
ing with normal saline and discarding the superna-
tant, the pellet was similarly resuspended stirred 
and 15 μL was loaded on to a slide glass covered 
by a piece of 18×18 coverslip for the bright field 
microscopic observation. 
2. Confirmation of the typical morphology of 
mulberry cells and mulberry bodies
The characteristic of mulberry body excret-
ed in the urine was a spiral body. Epithelial cells 
field with mulberry bodies are called mulberry 
cells. 
3. Confirmation of the origin of mulberry cells 
and mulberry bodies
After preparation of the urinary sediment, a 
non-fixed sediment suspension was prepared and 
processed by Sudan III staining and observed 
under a polarizing microscope to confirm the na-
ture of the spiral structures. In order to confirm 
the nature of the components exhibiting a spiral 
structure and the cells filled with them, 100 μL of 
non-fixed sediment suspension were smeared on 
to a slide glass coated with silane after cytospin. 
We conducted immunohistochemistry (IHC) anal-
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ysis using anti podocalyxin goat IgG monoclonal 
antibody and anti Gb-3 mouse IgG monoclonal 
antibody (COSMO Bio Co.) as the primary anti-
bodies. Alexa Fluor 594TM Donkey anti goat IgG 
and Alexa Fluor 488TM Donkey anti mouse IgG 
(Invitrogen TM) were diluted to 500-fold with 
buffer (1% bovine albumin 0.1% sodium azide 
phosphate buffer) to be used as the secondary an-
tibodies. In order to recognize nuclei, DAPI (In-
vitrogen TM) was used after 1000-fold dilution 
with buffer (1% bovine albumin and 0.1% sodium 
azide phosphate buffer). 
4. The evaluation method for mulberry cells 
and mulberry bodies after ERT
We observed the urinary excretion of mulberry 
cells and mulberry bodies after ERT. The evalua-
tion method used so far was a qualitative evalua-
tion to determine the structures were excreted in 
the urinary sediment or not (positive or negative). 
The existing evaluation method was sufficient as a 
screening test for Fabry disease. But in this study, 
we carried out monitoring, focusing on the effect 
of ERT, and determined the number of cells/bod-
ies per low power field (LPF). Daily excretion by 
calculating the non-centrifugal urinary equivalent 
(μL) of the whole field (WF) from the equivalent 
(μL) other than the centrifuge and dividing by the 
urinary creatinine value (mg/dL). The counting 
method for mulberry cells and mulberry bodies is 
shown in Figure 1. 
IV. Results
1. Urine collection, specimen preparation, and 
microscopy
We compared the appearance of mulberry cells 
and mulberry bodies in non-centrifugated urine 
specimens and the urine specimens processed 
by washing with normal saline, as needed. After 
washing with normal saline, no difference was ob-
served in the appearance and the detection rate in 
the urine. Regarding the scales of magnification 
used, it was difficult to confirm the structures at 
a magnification of 100X. The magnification of 
200X was sufficient to confirm the magnification 
of 400X allowed the structures to be visualized in 
detail (Figure 2). 
Figure 1, a typically aggregated mulberry bod-
ies and a typical mulberry cell with several 
mulberry bodies (unstained, 400X). A, there 
are six mulberry bodies which aggregate. The 
margin of mulberry body is obviously distinct. 
B, there is a mulberry cell with several mul-
berry bodies. When an epithelial cell contains 
mulberry bodies within the cytoplasm, the 
epithelial cell will be defined as a mulberry 
cell. The cytoplasm of epithelial cell is blur 
but the mulberry bodies are dis-tinct, which is 
a mulberry cell. 
Figure 2, two clusters of unstained aggregated mul-
berry bodies. Figures A, B, and C, the same 
and unstained mulberry bodies in different 
magnification (100X, 200X, and 400X), which 
aggregate in a cluster. Figures D, E, and F, the 
same and unstained mulberry bodies in differ-
ent magnification, which aggregate in a cluster. 
The unstained mulberry bodies are washed 
by the normal saline. The characteristics of 
mulberry body are not significantly changed 
and the margin of mulberry body still distinct 
with high refraction. 
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2. Confirmation of the typical morphology of 
mulberry cells and mulberry bodies 
The mulberry cell meant a cell filled with mul-
berry bodies with were with typical spiral struc-
tures. The mulberry body also had a clear spiral 
structure (Figure 3).
3. Confirmation of the origin of the mulberry 
cells and mulberry bodies
The component exhibiting a spiral structure 
showed weak pale yellow-orange staining by Su-
dan III and the Maltese cross birefringence was 
confirmed under a polarizing microscope. The 
oval fat body showed a strongly positive pale 
yellow-orange staining by Sudan III staining 
and Maltese cross birefringence under a polariz-
ing microscope (Figure 4). Glomerular epithelial 
cells exhibiting vacuolar degeneration in the renal 
biopsy tissue showed a positive fluorescent anti-
body staining for Gb-3. In the smear of the urine 
sediment, components exhibiting a spiral struc-
ture. The spherical cells which were larger than 
a leukocyte were with a positive staining for anti 
podocalyxin goat IgG monoclonal antibody, anti 
Gb-3 mouse IgG monoclonal antibody, and DAPI. 
These cells that were presumed to be derived 
Figure 3, the unstained mulberry cells and mulberry 
bodies from the second son and the mother. Fig-
ure A, a typical mulberry cell from the second 
son. Figure B, a typical mulberry body from the 
second son. Figure C, a typical mulberry cell 
from the mother. Figure D, a typical mulberry 
body from the mother. 
Figure 4, the differences between a mulberry cell 
and an oval fat body. Figures A, B, and C are 
mulberry cells. Figures D, E, and F are oval fat 
body. Figure B is the polarized image of figure 
A, the polarized mulberry bodies with refractive 
Maltese crosses. Figure E is the polarized image 
of figure D, the polarized fat droplets of the 
oval fat body with refractive Maltese crosses. 
Figure C (Sudan III stain), a stained mulberry 
cell. The spiral structure within a mulberry 
body is obvious. Figure F (Sudan III stain), a 
stained oval fat body. The stained fat droplets 
like a swollen orange ball. 
Figure 5, the IHC images of the mulberry cells from 
the urinary sediment smear. The red color is 
podocalyxin, the green the Gb3, and the blue 
the nuclei. All of the images are with posi-
tive reactions for DAPI (blue). Figure A, the 
strong positive reaction of podocalyxin and the 
weak positive reaction of Gb3. Figure B, the 
strong positive reaction of podocalyxin and the 
positive reaction of Gb3. Figure C, the weak 
positive reaction of podocalyxin and the strong 
positive re-action of Gb3. Figure D, E and F 
the negative reaction of podocalyxin and the 
positive reaction of Gb3. 
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from the glomerular epithelial cells that were 
positive for anti podocalyxin goat IgG monoclo-
nal antibody-negative, anti Gb-3 mouse IgG anti-
body-positive, and DAPI-positive (Figure 5).
4. The evaluation method for the excreted mul-
berry cells and mulberry bodies after ERT
In the son with classic Fabry disease, 5.1×104 
mulberry cells/gCr and 1.31×105 mulberry bod-
ies/gCr were excreted in the urine per day during 
ERT. In the mother, with hemizygous Fabry dis-
ease, 3.44×104 mulberry cells/gCr and 3.53×105 
mulberry bodies/gCr were excreted in the urine 
per day before ERT. The excreted mulberry cells 
and mulberry bodies were 11.73×104 cells/gCr and 
15.71×105 bodies/gCr per day during the ERT. Af-
ter ERT for 7 months, the excreted mulberry cells 
and mulberry bodies were 7.69×104 cells/gCr and 
6.87×105 bodies/gCr per day. 
V. Discussion
In order to expect the effect of suppressing 
the progression of various organ disorders in Fab-
ry disease, sufficient initiation of ERT should be 
considered at an early stage, and a clinical study 
that can explain the appropriate initiation timing 
of ERT and the criteria by which the effect of initi-
ation. As one of the indicators, mulberry cells and 
mulberry bodies in urine sediment are considered 
to play an important role.
In this study, we demonstrated a noninvasive-
ly standardized protocol to identify and quantita-
tively evaluate the presence of urinary mulberry 
cells or mulberry bodies of Fabry disease. There-
fore, we proposed the standardized protocol for 
the mulberry cells and mulberry bodies in urinary 
sediments as an index for the early diagnosis. This 
standardized protocol could also be applied for the 
evaluation of ERT. 
Most of the urine specimens for the routine 
tests are the random urine from the mid-stream. 
The appearance of mulberry cells and mulberry 
bodies in random urine specimens was compared 
between unprocessed urine samples and urine 
samples washed with physiological saline, and the 
results revealed no differences in the appearance or 
detection rate. Since washing with physiological 
saline reduces mulberry cells and mulberry bod-
ies and may cause underestimation, urine samples 
used for testing may be urine at any time, including 
urine samples used for other tests. it was thought. 
In regard to the degree of magnification needed for 
microscopic examination, it is described in Aims 
of the Guidelines on Urinary Sediment Examina-
tion Procedures Proposed by the Japanese Com-
mittee for Clinical Laboratory Standards (JCCLS) 
7) (Special Issue) that urinary sediments should be 
examined at 400 magnification. However, in order 
to detect Fabry disease efficiently and early, it is 
necessary to screen mulberry cells and mulberry 
bodies at 200 magnifications and count mulberry 
cells and mulberry bodies in all fields at 400 mag-
nifications and report the emission amount. We 
thought that it was desirable.
Regarding the morphology of mulberry cells 
and mulberry bodies, a typical spiral structure was 
observed before ERT. 
To confirm the origin of the spiral structures 
and identify mulberry cells and mulberry bodies, 
we applied Sudan III staining and polarization 
microscopy. The mulberry cells and mulberry 
bodies showed pale yellow-orange staining with 
Sudan III and Maltese cross birefringence by a 
polarizing microscope. The origin of the mulberry 
body found in urine was thought to be fat glob-
ules containing cholesterol esters and phospho-
lipids. Furthermore, since they showed positive 
immunohistochemical staining with anti-Gb-3 
antibody, they were considered as being derived 
from fat globules in which Gb-3 containing cho-
lesterol ester and phospholipid were accumulated. 
The oval fat body, which were morphologically 
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similar components, showed strongly positive 
pale yellow-orange staining with Sudan III, and 
although there was a difference in the intensity of 
staining as compared to that of mulberry bodies, 
differentiation between the two may not be reli-
able by this method. This component also showed 
Maltese cross birefringence under polarized light 
microscopy. Becker et al.8) reported that screen-
ing for Maltese cross birefringence in lipid par-
ticles under a polarizing microscope is effective 
for the detection of Fabry disease. However, the 
oval fat bodies excreted in nephrotic syndrome 
and fat-containing cells excreted in other diseases 
may also show the Maltese cross birefringence un-
der a polarizing microscope, so that it may not be 
as a usefully useful a screening method for Fabry 
disease. 
There are few reports on the origin of mulber-
ry cells excreted in the urine. Using anti-CD77 
antibody, it was reported that epithelial cells with 
accumulated GL3 are exfoliated into the urine9). 
However, the origin of the GL3-accumulated ep-
ithelial cells has not been proven. Therefore, IHC 
was performed to determine whether glomerular 
epithelial cells showing accumulation of Gb-3 
were excreted in the urine or not. The cells that 
have a spiral structure and the cells that are larger 
than the leukocytes that contain them and are larg-
er than the leukocytes were anti-podocalyxin an-
tibody-positive, anti-Gb-3 antibody-positive, and 
DAPI-positive are presumed to be derived from 
the glomerular epithelial cells. Cells that were 
anti-podocalyxin antibody-negative, anti-Gb-3 
antibody-positive, and DAPI-positive were also 
observed, and were considered to be derived from 
renal tubular epithelial cells, because the cells 
were spherical and the marginal structure of the 
cells was serrated. Until now, the number of uri-
nary podocytes in healthy subjects is reported to be 
<0.5/mgCr, whereas that in patients with glomer-
ular disease is higher than 10/mgCr10). The reason 
why glomerular epithelial cells can be easily be 
detected in the urine of patients with Fabry disease 
is that the glomerular epithelial cells are impaired 
by the accumulation of Gb-3 and are easily exfo-
liated into the urine. Trmarchi et al.11) reported the 
presence of glomerular epithelial cells among ex-
foliated cells in the urine using podocalyxin and 
synaptopodin in patients with Fabry disease. Fur-
thermore, it is reported that podocalyxin may be 
lost in patients with Fabry disease. Therefore, it is 
highly possible that the origin of mulberry cells is 
glomerular epithelial cells, and it is important to 
confirm this origin using podocalyxin and synap-
topodin. For monitoring Gb-3 accumulation after 
ERT, LysoGb3 is used as an indicator12). However, 
since it is expensive and results take a long time, a 
test that is rapid and cheap and can be performed 
anywhere is desired. We believe that a test that can 
meet this expectation is the detection of mulberry 
cells and mulberry bodies in the urinary sediment. 
Urinary sediment examinations for mulberry cells 
and bodies have so far been qualitative, that is, 
positive or negative, and detailed evaluation of the 
effects of ERT was not possible with such evalua-
tion. However, our method is useful, in that it en-
ables quantitative evaluation of the daily excretion 
of mulberry cells and mulberry bodies to grasp 
the accumulation state of Gb-3 in the renal tissue 
and also evaluate the effect of ERT. Comparison 
of the daily excretion of mulberry cells and mul-
berry bodies between urinary protein-negative 
and urinary protein-positive patients after ERT in 
patients with Fabry disease showed that the uri-
nary protein-negative patients showed disappear-
ance of mulberry cell excretion and decrease of 
mulberry body excretion, with maintenance of the 
renal function. On the other hand, in the urinary 
protein-positive patients, while the amount of 
mulberry bodies excreted decreased, the excretion 
of mulberry cells persisted unabated, and the renal 
function declined, often necessitating dialysis13). 
These results suggest that quantitative evaluation 
of the daily excretion of mulberry cells and mul-
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berry bodies in the urine may allow evaluation of 
the effect of ERT and of the renal prognosis in pa-
tients with Fabry disease.
It has been reported that before the start of 
ERT, the higher the urinary protein excretion, the 
faster the deterioration of renal function14), and the 
higher the urinary protein excretion, the lower the 
inhibitory effect of ERT on the renal function de-
terioration15). Therefore, it is considered important 
to monitor the morphology of the mulberry cells 
and mulberry bodies based on standard testing 
methods and to quantitatively monitor their daily 
excretion before proteinuria becomes apparent.
VI. Conclusions
The well distinguishing for the morpholog-
ical characteristics about the mulberry cells and 
mulberry bodies from the cells with fat droplets 
are important with a bright field microscope. The 
magnification of 200X is useful for the screening 
of the mulberry cells and mulberry bodies. The 
magnification of 400X for the whole field identifi-
cation (differential counting for the mulberry cells 
and mulberry bodies) is necessary. A quantitative 
count of the mulberry cells and mulberry bodies is 
a valuable test for the evaluation of ERT.
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